Search Results - Max Lataillade
- Showing 1 - 5 results of 5
-
1
Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants by Ying Zhang, Mark Bush, Parto Yazdani, Joyce Zhan, Bo Wen, Veronica Bainbridge, Brian R. Wynne, Samit Joshi, Max Lataillade
Published in Pharmacology Research & Perspectives (2023-12-01)Get full text
Article -
2
Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing. by Max Lataillade, Jennifer Chiarella, Rong Yang, Michelle DeGrosky, Jonathan Uy, Daniel Seekins, Birgitte Simen, Elizabeth St John, Elizabeth Moreno, Michael Kozal
Published in PLoS ONE (2012-01-01)Get full text
Article -
3
Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects by Shaili Gupta, Max Lataillade, Tassos C. Kyriakides, Jennifer Chiarella, Elizabeth P. St. John, Suzin Webb, Elizabeth A. Moreno, Birgitte B. Simen, Michael J. Kozal
Published in Viruses (2014-09-01)Get full text
Article -
4
Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study. by Max Lataillade, Jennifer Chiarella, Rong Yang, Steven Schnittman, Victoria Wirtz, Jonathan Uy, Daniel Seekins, Mark Krystal, Marco Mancini, Donnie McGrath, Birgitte Simen, Michael Egholm, Michael Kozal
Published in PLoS ONE (2010-06-01)Get full text
Article -
5
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1 by Judith A. Aberg, Bronagh Shepherd, Marcia Wang, Jose V. Madruga, Fernando Mendo Urbina, Christine Katlama, Shannon Schrader, Joseph J. Eron, Princy N. Kumar, Eduardo Sprinz, Margaret Gartland, Shiven Chabria, Andrew Clark, Amy Pierce, Max Lataillade, Allan R. Tenorio
Published in Infectious Diseases and Therapy (2023-09-01)Get full text
Article
